Healthcare Global Enterprises · NSE: HCG · BSE: 539787

Q4 FY20 results · Jan–Mar 2020

Healthcare Global Enterprises reported revenue from operations of ₹270.37 crore (up 5.2% from Q4 FY19) and net loss of ₹50.44 crore for Q4 FY20 (Jan–Mar 2020), on a consolidated basis.

Consolidated · ₹ crore
Item	Q4 FY20	Q4 FY19	YoY	Q3 FY20	QoQ
Revenue from operations	270.37	257.10	+5.2%	277.93	−2.7%
Other income	1.69	4.05	−58.3%	2.46	−31.3%
Total income	272.06	261.15	+4.2%	280.39	−3.0%
Profit before share of associates & JVs and tax	(40.14)	(2.93)	Loss widened	(25.62)	Loss widened
Share of profit/(loss) of associates & JVs	(1.54)	(5.25)		(2.22)
Net profit for the period	(50.44)	(10.88)	Loss widened	(29.16)	Loss widened
Attributable to shareholders of the company	(43.58)	(8.72)	Loss widened	(22.81)	Loss widened
EPS, basic (₹)	(4.91)	(0.99)	Loss widened	(2.57)	Loss widened
Net margin (%)	-18.7	-4.2		-10.5

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q4 FY20	Q4 FY19	YoY	Q3 FY20	QoQ
Revenue from operations	171.99	165.61	+3.9%	172.98	−0.6%
Other income	2.92	7.13	−59.0%	3.13	−6.7%
Total income	174.91	172.74	+1.3%	176.11	−0.7%
Profit before tax	(49.49)	6.10	Turned loss	(7.54)	Loss widened
Net profit for the period	(43.55)	3.03	Turned loss	(4.27)	Loss widened
EPS, basic (₹)	(4.91)	0.35	Turned loss	(0.48)	Loss widened
Net margin (%)	-25.3	1.8		-2.5

Consolidated

Filed with BSE: 29 Jul 2020, 16:09 IST
Board meeting: 28 Jul 2020
Period: 01 Jan 2020 to 31 Mar 2020
Review status: Audited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 29 Jul 2020, 16:09 IST
Board meeting: 28 Jul 2020
Period: 01 Jan 2020 to 31 Mar 2020
Review status: Audited
Source: XBRL filing on BSE